Story perspectives

FDA Approves Fosfomycin to Combat Rising UTI Resistance

11/6/2025

38 6

Summary

Story summary

The U.S. Food and Drug Administration approved fosfomycin (Contepo) for treating complicated urinary tract infections in adults, including acute pyelonephritis.
In the ZEUS trial, fosfomycin achieved a 63.5% overall success rate, compared with 55.6% for piperacillin/tazobactam.
Common adverse reactions include transaminase elevations and hypokalemia.
Meitheal Pharmaceuticals manufactures fosfomycin and has a portfolio of over 70 products.
The approval addresses rising antimicrobial resistance in the United States.

1 of 1

Story summary

The U.S. Food and Drug Administration approved fosfomycin (Contepo) for treating complicated urinary tract infections in adults, including acute pyelonephritis.
In the ZEUS trial, fosfomycin achieved a 63.5% overall success rate, compared with 55.6% for piperacillin/tazobactam.
Common adverse reactions include transaminase elevations and hypokalemia.
Meitheal Pharmaceuticals manufactures fosfomycin and has a portfolio of over 70 products.
The approval addresses rising antimicrobial resistance in the United States.